While this statistic does not concur with the low ALCL incidence of 1.2 million of the general population, it does suggest an early event is possible; indeed, the NPM promoter that drives expression of NPM-ALK in humans is active throughout thymic development [86]. The gene discussed is NPM1; the disease is anaplastic large cell lymphoma.